Patient-Centered Endpoints

Patient perspectives can shape trial design.

Design your trials around patients as well as products. With tools to measure, analyze and improve patient experience in trials, support regulatory approval and differentiate your drug for payers.

A difference you can measure

As part of the 2016 21st Century Cures Act, the FDA allowed companies to provide "data summaries," real world evidence, and anecdotal data to support approval of new indications, including a required statement on patient experience data. That reflects a growing number of patients who want their voices to be heard, from trials to treatment plans.

IQVIA can help you meet those expectations and make the patient experience a meaningful measure of therapeutic value.

IQVIA’s Clinical Outcome Assessment (COA) Process

Our solutions are designed to dovetail with existing internal capabilities, so from strategy development to regulator and payer communications, you have what you need to amplify the patient perspective.

The FDA and EMA have begun to strongly request that Patient Reported Outcomes data be considered in the assessment of clinical trial endpoints
Jean Paty, Vice President, Patient Centered Endpoints, IQVIA

Seamlessly integrate digital data

Widespread use of mobile devises is bringing patients closer to trials than ever before, from enabling remote recruitment to giving patients an "always on" way to report information about symptoms and quality of life.

IQVIA's e-Clinical Outcome Assessment (eCOA) seamlessly integrates self-reported data from patients into the overall endpoints reporting process. So internal and external stakeholders can seamlessly extract insights from traditional and digital data.

Start with experiences, not assumptions

Beyond meeting regulatory and payer asks, taking patient feedback into account can change the way your trials work, and the quality of your outcomes. Listening to patients can give you a different point of view on what constitutes better treatment. So you can design trials that respond to what patients value, and get to better treatments faster.

That in turn can support significant differentiation and attendant advantages, both in gaining market access, achieving regulatory acceptance and finding the highest and best applications for your therapy.

Patient experience data industry experts

As an increasingly important cornerstone in successful intervention development, patient experience data (PED) can help developers make decisions about which interventions will most likely meet unmet needs and live up to the promise of maximizing health and well-being.

Our team of experts are specialists in PED. Our recently published book – Using Patient Experience Data to Evaluate Medical Interventions – provides a robust overview of how PED can be generated during intervention development, and how it can be utilized to inform decision-making at the regulatory, payer, healthcare professional and patient levels. Contact us to learn how to apply these principles in your product development.

IQVIA COA Licensing & Usage
Learn more about all Clinical Outcome Assessments (COAs) available for licensing through IQVIA

Other consulting solutions

Contact Us